Alibaba's Chip Arm Eyes Hong Kong, And The AI Map Shifts
Published on 18 November 2026
Read article
Listen to article
6:21Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Let’s be honest, shall we? The investment world can feel like a particularly frantic casino at times. One minute, everyone is piling into some tech firm that promises to revolutionise how we order a takeaway, and the next, it’s all gone pear-shaped. It’s exhausting. Amidst this chaos, I find myself increasingly drawn to the quiet, dependable, and dare I say, slightly boring world of healthcare. Because while trends come and go, one thing is stubbornly certain. People will always get ill, and they will always get old.
This isn't a sector built on hype. It’s built on the fundamental, non-negotiable realities of human life. You don’t cancel a prescription because the stock market had a bad day, nor do you postpone a hip replacement because of inflation figures. This inelastic demand is what gives the sector its backbone. It’s the sensible adult in a room full of excitable teenagers.
And the tailwinds here are not fleeting. We are living in an ageing world. The World Health Organisation isn't shy about projecting that healthcare spending will outpace GDP growth in most developed nations. This isn’t a speculative punt on a new technology. It’s a demographic certainty, a slow-moving but powerful current that could lift the entire sector for decades to come. The question for an investor, then, is not if this is a solid theme, but how to get a piece of it.
When you look at the big players, Johnson & Johnson often comes to mind first, and for good reason. To me, it’s less a single company and more a sprawling healthcare empire. It doesn’t just make blockbuster drugs. It also makes the surgical tools in the operating theatre and the plasters in your bathroom cabinet. This diversification is its superpower. When one area faces a headwind, like a patent expiring on a key drug, the other divisions are there to provide ballast.
This structure has allowed it to become what the Americans call a ‘Dividend Aristocrat’, which is a fancy way of saying it has reliably paid and increased its dividend for over half a century. In a world of fleeting promises, that sort of track record speaks volumes. It suggests a business built on foundations of stone, not sand. To me, this makes Johnson & Johnson (Healthcare Diversification) a fascinating case study in corporate resilience.
Of course, J&J isn't the only game in town. You also have the focused powerhouses like Pfizer and Merck. Pfizer, fresh from its starring role in the pandemic, is now sitting on a mountain of cash, which it can plough into research for the next big breakthrough. It’s a bet on pure innovation. Merck, on the other hand, shows the power of dominating a niche. Its cancer drug, Keytruda, has been a phenomenal success, demonstrating how getting one thing spectacularly right can drive immense value. These companies offer a different flavour, a more concentrated wager on scientific discovery.
Now, I wouldn't want you to think this is a risk-free ride. Nothing is. The path from a laboratory to a pharmacy is long, expensive, and littered with failures. Patents, the very things that protect a blockbuster drug’s profits, eventually expire, opening the door to a flood of cheaper generics. And let’s not forget the politicians, who love nothing more than to make noise about drug pricing. These are real risks that can, and do, affect share prices. Any sensible investor needs to go in with their eyes wide open. But for those seeking a degree of stability in their portfolio, the long-term case for healthcare remains, in my view, remarkably compelling.
View the full Basket:Johnson & Johnson (Healthcare Diversification)
View the full Basket:Johnson & Johnson (Healthcare Diversification)
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 18 November 2026
Read article
Published on 18 November 2026
Read article
Published on 18 November 2026
Read article
Published on 17 November 2026
Read article
Published on 17 November 2026
Read article